| Symbol | NMRA |
|---|---|
| Name | NEUMORA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 260 ARSENAL PLACE,SUITE 1, WATERTOWN, Massachusetts, 02472, United States |
| Telephone | +1 857 - 760-0900 |
| Fax | — |
| — | |
| Website | https://www.neumoratx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001885522 |
| Description | Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimers disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinsons disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Additional info from NASDAQ: |
(70% Positive) NEUMORA THERAPEUTICS, INC. (NMRA) Announces Enrollment Update for endpoint Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreNeumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
Read moreBurow Kristina 🟢 acquired 80.0K shares (1 derivative) of Neumora Therapeutics, Inc. (NMRA) at $1.86 Transaction Date: May 27, 2026 | Filing ID: 000174
Read more(99% Neutral) NEUMORA THERAPEUTICS, INC. (NMRA) Announces Regulatory Update
Read moreNew Form SCHEDULE 13G/A - Neumora Therapeutics, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000905148-26-002417 <b>Size:</b> 11 KB
Read more(30% Negative) NEUMORA THERAPEUTICS, INC. (NMRA) Reports Q2 2026 Financial Results
Read moreNew Form SCHEDULE 13G/A - Neumora Therapeutics, Inc. <b>Filed:</b> 2026-05-04 <b>AccNo:</b> 0002005369-26-000023 <b>Size:</b> 18 KB
Read moreNew Form DEFA14A - Neumora Therapeutics, Inc. <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001193125-26-161519 <b>Size:</b> 819 KB
Read moreNew Form DEF 14A - Neumora Therapeutics, Inc. <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001193125-26-161489 <b>Size:</b> 3 MB
Read moreNeumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06546995 | Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults W… | Phase1 | Alzheimer's Disease | Completed | 2024-07-09 | 2025-11-19 | ClinicalTrials.gov |
| NCT06429722 | To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Parti… | Phase2 | Major Depressive Episode Associated With Bipolar II Disorder | Completed | 2024-05-13 | 2025-05-30 | ClinicalTrials.gov |
| NCT06058039 | Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depr… | Phase3 | Major Depressive Disorder | Active_Not_Recruiting | 2023-12-21 | 2026-06-01 | ClinicalTrials.gov |
| NCT06058013 | Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants … | Phase3 | Major Depressive Disorder | Active_Not_Recruiting | 2023-12-20 | 2026-06-01 | ClinicalTrials.gov |
| NCT06029439 | Study to Assess the Safety and Effectiveness of NMRA-335140-501 | Phase3 | Major Depressive Disorder | Active_Not_Recruiting | 2023-11-10 | 2027-06-01 | ClinicalTrials.gov |
| NCT06029426 | Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participant… | Phase3 | Major Depressive Disorder | Completed | 2023-09-20 | 2025-01-15 | ClinicalTrials.gov |
| NCT04221230 | Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo | Phase2 | Major Depressive Disorder | Completed | 2020-01-03 | 2022-06-23 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| NMRA-335140 | Other | Phase PHASE3 | Major Depressive Disorder | ACTIVE_NOT_RECRUITING | NCT06029439 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT06546995 |
| NMRA-323511 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT06546995 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT06546995 |
| NMRA-323511 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT06546995 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT06546995 |
| NMRA-323511 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT06546995 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT06546995 |
| NMRA-323511 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT06546995 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT06546995 |
| NMRA-323511 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT06546995 |
| NMRA-335140 | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT06029439 |
| NMRA-335140 | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT06029439 |
| NMRA-335140 | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT06029439 |
| NMRA-335140 | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT06029439 |
| NMRA-335140 | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT06029439 |
| NMRA-335140 | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT06029439 |
| Placebo | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT04221230 |
| NMRA-335140 | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT04221230 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT06546995 |
| NMRA-323511 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT06546995 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT06029426 |
| NMRA-335140 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT06029426 |
| Placebo | Other | Phase PHASE2 | Major Depressive Episode Associated With Bipolar II Disorder | COMPLETED | NCT06429722 |
| NMRA-335140 80 mg | Other | Phase PHASE2 | Major Depressive Episode Associated With Bipolar II Disorder | COMPLETED | NCT06429722 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | ACTIVE_NOT_RECRUITING | NCT06058039 |
| NMRA-335140 | Other | Phase PHASE3 | Major Depressive Disorder | ACTIVE_NOT_RECRUITING | NCT06058039 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | ACTIVE_NOT_RECRUITING | NCT06058013 |
| NMRA-335140 | Other | Phase PHASE3 | Major Depressive Disorder | ACTIVE_NOT_RECRUITING | NCT06058013 |
| NMRA-335140 | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT06029439 |
| NMRA-323511 | DRUG | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT06546995 |
| NMRA-335140 80 mg | DRUG | Phase PHASE2 | Major Depressive Episode Associated With Bipolar II Disorder | COMPLETED | NCT06429722 |
| Placebo | DRUG | Phase PHASE3 | Major Depressive Disorder | ACTIVE_NOT_RECRUITING | NCT06058013 |
| NMRA-335140 | DRUG | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT06029439 |